跳至主要内容
临床试验/NL-OMON50000
NL-OMON50000已完成不适用

Wishing to decrease Aquaresis in ADPKD patients Treated with a V2Ra; the Effect of Regulating protein and salt - WATER

niversitair Medisch Centrum Groningen0 个研究点目标入组 12 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
12

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • •1. Diagnosis of ADPKD, based upon modified Ravine criteria, or documented by
  • •their nephrologist or internist.
  • •2. Prescribed tolvaptan as part of routine clinical care in the highest dose
  • •tolerable (preferably 120 mg daily)
  • •3. Age >= 18 years.
  • •4. eGFR >30 ml/min/1.73m2.
  • •5. Providing informed consent.
  • •6. Compliance to the recommended diet (<9 grams of salt per day, < 1,2 grams of
  • •protein per kg ideal bodyweight per day) at two consecutive times.

排除标准

  • •1. Patients who, in the opinion of the investigator may present a safety risk.
  • •2. Patients who are unlikely to adequately comply to the trial*s procedures
  • •(due for instance to medical conditions likely to require interruption or
  • •discontinuation, history of substance abuse or non-compliance).
  • •3. a. Patients taking medication likely to confound endpoint assessments
  • •(lithium, systemic corticosteroids, diuretics).
  • •3. b. Patients having concomitant illnesses likely to confound endpoint
  • •assessments (e.g. diabetes mellitus for which medication is needed or diabetes
  • •insipidus).
  • •4. Women who are pregnant or breastfeeding.
  • •5. Patients with limited access to water.
  • •6. Patients with an abnormal sense of thirst.

研究者

相似试验